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Summary This study reports on the frequency and disease association pattern of a number of gene rearrangements in a large panel of
lymphoid tumours (n = 94). We detected the t(1;14) translocation, involving rearrangement of the BCL - 1 locus, in 60% of mantle cell
lymphomas. The BCL - 2 gene, located at band 1 8q21, was rearranged in 42% of follicle centre lymphomas (FCL) and in 15% of diffuse large
B-cell (DLBC) lymphomas. In this study, 80% of the c-MYC rearrangements were detected in aggressive diffuse lymphoma subsets but,
interestingly, 9% of FCL showed involvement of t(8q24) translocation. In our study, rearrangements of the BCL-6 gene at band 3q27 were
found in 31% of DLBC lymphomas. Interestingly, 50% of the BCL-6 rearrangement positive lymphoma cases had coexisting gene
rearrangements involving all of the aforementioned gene loci. The molecular dissection of these genes will improve our understanding of the
genesis of the diverse clinicopathological subtypes.
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Non-Hodgkin's lymphomas (NHL) arise from the clonal expan-
sion of B (approximately 85%) and T lymphocytes (15%) that
have transformed as a result of DNA damage at various points in
lineage differentiation. They represent a heterogeneous group of
neoplasms that vary in their clinical presentation, response to treat-
ment and disease outcome. This clinicopathological diversity may
be mediated by the deregulation of different proto-oncogenes
together with the inactivation of different tumour-suppressor
genes. Previous studies have indicated correlations between
specific chromosomal abnormalities and defined subtypes ofNHL
(Koduru et al, 1987; Cotter, 1990). The most frequently observed
genetic abnormalities in NHL are reciprocal translocations. In
B-cell NHL, these events often result in the juxtaposition of proto-
oncogenes with the immunoglobulin genes (14q32, 22qll and
2p12) leading to transcriptional deregulation of the proto-oncogenes.
If these genes participate in the fine control mechanisms regu-
lating normal lymphocyte development, then their disruption may
help promote lymphomagenesis.
Recurring translocations in NHL include the t(14;18)(q32;q21)
detected in 50-70% of FCL in Europe (Dejong et al, 1989; Clark
et al, 1992; Lambrechts et al, 1992), the t(8;14)(q24;q32)
detectable in most Burkitt's lymphomas (Lenoir et al, 1982) and
the t(11;14)(q13;q32) detectable in 50-60% of mantle cell
lymphomas (MCL) (Raffeld and Jaffe, 1991; DeBoer et al, 1993).
The emergence of new techniques such as DNA fibre fluorescent
in situ hybridization (FISH) has increased the detection of 11q13
breakpoints to approximately 95% in MCLs (Vaandrager et al,
1996). These translocations 'trigger' the oncogenic conversion of
Received 9 August 1995
Revised 8 July 1996
Accepted 4 December 1996
Correspondence to: M Butler, Lab. 15-410, College of Physicians & Surgeons,
Columbia University, 630 West 168th Street, New York, NY 10032, USA
the anti-apoptosis gene BCL-2 (Bakhshi et al, 1985; Cleary and
Sklar, 1985; Tsujimoto et al, 1985), the proto-oncogene encoding
transcription factor c-MYC (Dalla-Favera et al, 1982; Taub et al,
1982) and the cell cycle regulation gene BCL-1 (CCNDIIPRADI)
(Arnold et al, 1989; Raffeld and Jaffe, 1991; Williams et al, 1991;
Komatsu et al, 1994), respectively, by deregulating their expres-
sion. The putative oncogene deregulated by the t(I 1 ;14)(q13;q32)
was identified by two groups of investigators and is located
approximately 120 kb telomeric from the major translocation
cluster (MTC) breakpoint region. The gene was originally named
PRADI because of its original recognition in parathyroid
adenomas (Arnold et al, 1989) but has now been officially named
CCNDJ. The gene encodes for cyclin Dl and is overexpressed in
nearly all cases of MCLs.
Recently, a translocation involving the 3q27 region with
numerous partner chromosomes (lq21, 2q21, 4pll, 4q27, 5ql3,
6q23, 6q25, 6p2l,7pl2, 8q24, llql3, 12pll, 12pll, 12q24, 15q21,
l6pl3, 14q32, 2pl2, 22qll) has been described in approximately
30% of diffuse lymphomas with a large-cell component (Bastard et
al, 1994; LoCoco et al, 1994). Several groups of investigators iden-
tified the gene involved in 3q27 translocations and named it BCL-6
or LAZ-3 and BCL-5 (Kerckaert et al, 1993; Ye et al, 1993a; Miki
et al, 1994). Translocations at 3q27 involving BCL-6 display atyp-
ical properties when compared with the previously characterized
lymphoma-associated translocations: (1) the partner chromosomes
are not limited to the Ig gene loci; (2) the coding region of BCL-6
remains on derivative 3 following all translocations described to
date; and (3) the breakpoints ofcommon (14q32) and variant (2pl2,
22q1 1) translocations both cluster in the 5' region of the gene. This
is in contrast to BCL- 1, BCL-2 and c-MYC rearrangements in which
the breakpoints of the Ig heavy-chain (14q32) and light-chain
(22q1 1 and 2p12) genes locate at opposite sides of the target genes
(Croce et al, 1985; Osada et al, 1989; Komatsu et al, 1994).
Interestingly, the reciprocal partner chromosomes of 3q27 may
mark the sites of known as well as yet to be identified gene loci.
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BCL-6 rearrangements have been suggested to be relatively specific
for large-cell lymphomas that occur de novo (i.e. without a
preceding follicular period) and also to define a BCL-2-independent
pathway of lymphomagenesis (LoCoco et al, 1994). However,
several groups of investigators have published findings of BCL-6
rearrangements in both follicular lymphomas as well as DLBC
lymphomas carrying t(14;18) that oppose the possibility of these
two events being exclusive of one another (Ohno et al, 1994; Otsuki
et al, 1995). The BCL-6 gene encodes for a zinc finger protein
which shares homologies with several transcription factors that
participate in the control of cell proliferation, differentiation and
organ formation (Bastard et al, 1992; Baron et al, 1993; Kerckaert
et al, 1993; Ye et al, 1993b).
The objectives of this study were to determine (1) the frequency
and (2) the disease specificity of BCL-1, BCL-2, c-MYC and BCL-
6 gene rearrangements in a large series of lymphoid malignancies
representative of the Irish population. Also, we discuss interesting
findings of several coexisting rearrangements in lymphoid malig-
nancies, with particular emphasis on those associated with the
BCL-6 gene.
MATERIALS AND METHODS
Patient materials
Fresh-frozen lymph node biopsy specimens were obtained from 94
non-Hodgkin's lymphoma (NHL) patients who attended the Mater
Misericordiae Hospital between January 1987 and March 1994.
The tumours were classified histologically according to the
Revised European-American Lymphoma (REAL) Classification
(Harris et al, 1994).
DNA extraction and Southern blot analysis
High molecular weight DNA was obtained by the standard sodium
dodecyl sulphate (SDS)/proteinase K and phenol chloroform
extraction method (Sambrook et al, 1989). For Southern blot
analysis, 10 gg of DNA was digested with the appropriate restric-
tion endonuclease, electrophoresed on a 0.8% agarose gel, de-
natured, neutralized and transferred to nylon membranes (Hybond
N+, Amersham). Filters were then hybridized with probes that had
been radiolabelled using a random primer DNA labelling kit
(Promega, Madison, WI, USA) with [a-32P]dCTP. After hybridiza-
tion, membranes were washed with 2 x standard saline citrate
(SSC) and 0.1% SDS at 65°C for 40 min followed by 0.2xSSC and
0.1% SDS at 65°C for 50 min. The membranes were then exposed
with intensifying screens at -70°C for 2-7 days.
DNA probes
The organization of the BCL-1 locus was investigated by
hybridization of BamHI, EcoRI and HindllI digested DNA with a
2.1-kb SstI fragment of the major translocation cluster (MTC)
breakpoint region of the BCL-1 gene (gift from Dr Y Tsujimoto,
Wistar, Philadelphia, PA, USA). The configuration of the BCL-2
gene was assessed by hybridization of EcoRI, HindIII and PstI
digested DNA with a 3.5-kb EcoRI-HindIII fragment cloned from
the major breakpoint region (mbr) of the BCL-2 gene (courtesy of
Dr Y Tsujimoto). Two different probes were used to assess the
configuration of the c-MYC gene; HindIII and EcoRI-digested
DNA were probed with the first exon probe, a 1.9-kb ClaI-SstI
fragment and the third exon probe, a 1.5-kb EcoRI-HindllI frag-
ment (both gifts from Dr I Kirsch, National Cancer Institute,
Bethesda, MD, USA). Finally, the BCL-6 gene was analysed by
hybridization of BamHI and XbaI DNA digests with a 4.0-kb Sacl
probe (kindly provided by Dr BH Ye, College of Physicians and
Surgeons, Columbia University, NY, USA).
RESULTS
Table 1 gives the frequencies of the gene rearrangements BCL-1,
BCL-2, c-MYC and BCL-6 in the total cohort of 94 NHL.
Representative results of hybridization analysis with the major
breakpoint region probe of BCL-6 to tumour DNAs digested with
BamHI are presented in Figure 1.
We detected rearrangements,of BCL-1 at the MTC breakpoint
region in 60% (6 out of 10) of MCLs. In addition, this was
detected in a case of small lymphocytic lymphoma (1 out of 5;
20%), as well as in 2 of 33 (6%) diffuse large B-cell (DLBC)
lymphomas.
Table 1 Incidence of gene rearrangements in a panel of non-Hodgkin's lymphoma
Lymphoma subtypea BCL-1 BCL-2 c-MYC BCL-6
Precursor B-lymphoblastic 0/1 0/1 0/1 0/1
B-cell lymphocytic leukaemia/lymphocytic lymphoma 1/5 (20%) 0/4 0/5 0/5
Mantle cell lymphoma 6/10 (60%) 0/6 0/8 0/6
Follicular centre lymphoma, follicular
Grade 0/8 4/6 (67%) 0/6 0/6
Grade II 0/8 2/8 (25%) 1/5 (20%) 0/7
Grade III 0/3 2/3 (67%) 0/3 1/3 (33%)
Follicular centre lymphoma, diffuse small cell (provisional) 0/11 3/9 (33%) 1/8 (13%) 0/9
Diffuse large B-cell 2/33 (6%) 4/27 (15%) 4/28 (14%) 9/29 (31%)
Primary mediastinal large B-cell lymphoma 0/1 0/1 0/1 0/1
Burkitt's lymphoma 0/1 0/1 1/1 (100%) 0/1
High-grade B-cell lymphoma, Burkitt-like (provisional) 0/4 0/4 1/4 (25%) 0/3
Precursor T-lymphoblastic lymphoma 0/3 0/3 2/4 (50%) 0/2
Peripheral T-cell lymphomas 0/5 0/4 0/5 0/4
Overall frequency 9/93 (10%) 15/77 (19%) 10/79 (13%) 10/77 (13%)
aClassified according to the REAL (Revised European American Lymphoma) classification.
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Figure 1 Southern blot showing rearrangement of BCL-6 with the Sacd
major breakpoint region probe in DLBC lymphomas. Normal DNA (N-lane 1)
shows a germline band of 11 kb in this Bam HI digest. Tumour DNAs are
numbered 1-6 inclusive. Rearranged bands are indicated by the arrows
The t(14;18) chromosomal translocation, involving rearrange-
ment of BCL-2, was the most common genetic abnormality
encountered in our series of NHLs (19%; 15 out of 77). Bcl-2 was
rearranged in 42% (11 out of 26) of follicle centre lymphomas
(FCL), in 15% (4 out of 27) of DLBC lymphomas and in no other
lymphoma subtypes.
Alterations of the c-MYC locus were observed in 25% (one out
of four) of high-grade B-cell lymphomas (Burkitt-like, provi-
sional), 50% (two out of four) of precursor T-lymphoblastic
lymphomas, 14% (4 out of 28) of DLBC lymphomas and in the
single Burkitt's lymphoma case (one out of one; 100%). A FCL
(grade II) demonstrated rearrangement of c-MYC; this particular
patient had a previous FCL (grade I) and the patient died 30
months following diagnosis. We also report a rare finding of a
lymphoma case, again of follicle centre cell origin (areas of diffuse
histology seen), that demonstrated both c-MYC and BCL-2
rearrangements. This patient died 36 months from diagnosis.
In our study, we report BCL-6 rearrangements in 31% (9 out of
29) of DLBC lymphomas. One out of 25 (4%) FCLs were positive
for this rearrangement, which occurred in a FCL of large-cell
morphology. Immunophenotypic analysis showed that all tumours
displaying this rearrangement were of B-cell phenotype. Five of
ten (50%) of these tumours had additional gene rearrangements,
involving the BCL-2 gene in three cases, c-MYC and BCL-1 genes
in the two remaining cases. One of the DLBC lymphomas showing
a co-existing BCL-2 rearrangement had an antecedent history of a
FCL (grade I), and the DLBC lymphoma with a co-existing BCL-1
rearrangement had a previously reported low-grade lymphoma
(slide not available for review). The patient with both BCL-6 and
c-MYC rearrangements (biopsy specimen taken at time of diag-
nosis) died 7 months later.
DISCUSSION
Recurrent translocations and their corresponding molecular
counterparts, gene rearrangements, represent important mutational
mechanisms that characterize approximately 95% of NHL.
The t(I 1 ;14) translocation is detectable in nearly all MCLs by
applying novel DNA fibre FISH methodology. This lymphoma
subtype corresponds closely to centrocytic (CC) lymphoma in the
Kiel classification (Gerard-Marchant et al, 1974), lymphocytic
lymphoma of intermediate differentiation (IDL) by Berard et al
(1974) and diffuse small cleaved-cell (DSCC) lymphoma in the
Working Formulation (WF) (1982). The PRADJ/CCNDI gene is
now recognized as the once elusive gene involved in the t(1 q13)
breakpoint, and its expression is up-regulated in cell lines or disor-
ders carrying the t(I 1 ;14) translocation (Seto et al, 1992). This
gene encodes cyclin Dl, which plays an important role in cell
cycle regulation and the progression of cells through the G1-S
phase (Hunter et al, 1994).
In our study, we detected BCL-1 rearrangements in 60% (6 out of
10) of MCLs, a single case of lymphocytic lymphoma and in 6%
(2 out of 33) of DLBC lymphomas. These DLBC lymphomas may
actually represent blastic variants of previous MCLs, as this has
been reported to occur, albeit at a relatively low frequency. This
suggestion is partly substantiated by the knowledge that one of these
two cases had a known DSCC lymphoma (WF) which corresponds
closely to MCL in the REAL classification scheme (slide not avail-
able for review). Our findings of 60% of BCL-1 rearrangements in
MCLs correlate with the findings of five groups of investigators
who reported 49% (n = 77) of their IDUCC lymphomas positive for
this rearrangement (Medeiros et al, 1990; Williams et al, 1990,
1991; Wotherspoon et al, 1990; Athan et al, 1991). The reported
50-60% incidence of this rearrangement may be an underestimate
of the true frequency because most investigators analysed only the
MTC region of the BCL-1 locus. The advent of FISH technology has
given us a powerful tool to detect both clustered as well as scattered
breakpoints. This is well illustrated by Vaandrager et al (1996) who
applied DNA fibre FISH technology to successfully detect 1lq13
breakpoints in 95% (19 out of 20) of their MCLs, while their
previous Southem blot data gave a much lower frequency of 53%.
In the t(14;18) translocation, the joining region of the IgH gene
(14q32) is juxtaposed to the BCL-2 gene (18q21), which results in
the overexpression of a chimeric BCL-2/IgH message (Graninger
et al, 1987; Seto et al, 1988). Hockenberry et al (1990) showed that
the BCL-2 protein is able to block programmed cell death.
In our series, BCL-2 rearrangement was the most frequent
genetic abnormality occurring at 19%. Among the various
subtypes, we detected BCL-2 rearrangements in 42% of FCL and in
15% of diffuse lymphomas, suggesting its association mainly with
tumours of follicular histology. Previous investigators reported
BCL-2 rearrangements in 55-70% of follicular lymphomas
(Lambrechts et al, 1987; deJong et al, 1989; Clark et al, 1992) and
in 10-30% of diffuse lymphomas. However, the lower frequency
(42%) observed in our series of FCLs may be partly attributed to
the fact that only the major breakpoint region probe was used to
assess rearrangement status and this probe detects approximately
60% of t(18q21) translocations. Other investigators also included
the minor cluster region probe as part of their analysis.
In our study, we observed alterations of the c-MYC locus in
50% of T-lymphoblastic lymphomas, 25% of high-grade B-cell
lymphomas, 14% of DLBC lymphomas and in the single Burkitt's
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lymphoma case included in our study. These subtypes comprise
tumours that behave in a clinically aggressive manner. Previous
reports show involvement of the t(8q24) translocation in almost
all cases of Burkitt's lymphoma as well as in a subset of large-cell
lymphomas. The t(8;14) invariably results in deregulation of the
c-MYC oncogene, with subsequent overexpression of the gene
product. The MYC product has been shown to be a member of the
leucine zipper family of DNA-binding proteins and has been
implicated as a potent regulator of cellular proliferation (Stewart
et al, 1984). In this study, we report unusual occurrences of c-
MYC rearrangements in two FCLs. Other investigators have
reported rare or no cases of t(8q24) in their series of FCLs (Donti
et al, 1988; Juneja et al, 1990; Yano et al, 1992). Interestingly, we
found a case of FCL (showing areas of diffuse histology) positive
for both c-MYC and BCL-2 rearrangements. The patient's tumour
was clinically aggressive and the patient died 36 months after
diagnosis. It would be interesting to know whether the acquisition
of the c-MYC rearrangement influenced the tumour's progression
to a more aggressive subtype. However, we have no further
histology reports in medical records to support this hypothesis.
Also, we report a FCL (grade II) with involvement of t(8q24).
The patient's previous biopsy showed a grade I FCL which
recurred and progressed to a grade II FCL. The patient died
30 months later, which again reinforces the idea that the acquisi-
tion of this genetic anomaly may lead to the development of
tumours with poor prognostic implications. Isolated case reports
(Gauwerky et al, 1988; Lee et al, 1989) have appeared in the liter-
ature implicating c-MYC in the histological progression of some
low-grade follicular lymphomas. Studies in transgenic mice
provide an animal model for tumour progression in t(14;18)
lymphoma, showing that evolution into a more aggressive
lymphoma is accompanied by c-MYC rearrangements in half of
the cases (McDonnell et al, 1991).
Recently, much interest has centred on a newly described gene,
BCL-6, because of its involvement in a large subset of clinically
important DLBC lymphomas. Our data showed rearrangement of
BCL-6 to be the most frequent genetic abnormality detectable in
our series of DLBC lymphomas (3 1%; 9 out of 29). This incidence
is similar to previous reports - 29% of diffuse aggressive
lymphomas reported by Otsuki et al (1995), 36% reported by
LoCoco et al (1994) and 37% by Bastard et al (1994).
We detected 4% (1 out of 25) of FCLs to be positive for this
rearrangement; Bastard et al (1994) reported this specific alter-
ation in 13% (11 out of 84) and LoCoco et al (1994) in 6% (2 out
of 31) of their respective series of follicular lymphoma cases.
The tumours with BCL-6 rearrangements were all of B-cell
origin, and 50% had co-existing gene rearrangements. These
involved the BCL-2 gene in three cases, the BCL-1 gene in one
case and c-MYC in the remaining lymphoma. Two DLBC
lymphomas had coexisting BCL-6 and BCL-2 rearrangements.
This contrasts with the findings of LoCoco et al (1994) who report
the absence of BCL-2 rearrangement in their series of BCL-6-
rearrangement-positive DLBC (16 out of 45) lymphomas, hence
suggesting that BCL-6 may define an independent pathway from
BCL-2 in lymphomagenesis. However, our findings are substanti-
ated by others, who showed coexisting BCL-2 and BCL-6
rearrangements in transformed lymphomas (17%; 9 out of 52)
(Otsuki et al, 1995) as well as in de novo DLBC lymphomas (21%;
8 out of 39) (Bastard et al, 1994), thereby strongly suggesting that
these two events are unlikely to be exclusive of one another.
We show coexisting BCL-2 and BCL-6 rearrangements in a
DLBC lymphoma that had transformed from a low-grade FCL.
The original biopsy specimen (FCL, grade I) also demonstrated a
BCL-6 rearrangement. We also report a DLBC lymphoma demon-
strating both BCL-1 and BCL-6 rearrangements that had an
antecedent history of a low-grade lymphoma. The BCL-6
rearrangement status of the original biopsy is not known. The
question of BCL-6 participating in the transformation process of
some lymphoid malignancies remains unanswered; this needs to
be resolved by accumulating and analysing more cases accompa-
nied by clear medical history records. However, another consider-
ation is the fact that the partner chromosomes of BCL-6 are
numerous and may represent the sites of known, as well as of yet
uncharacterized, gene loci perhaps harbouring unidentified genes,
which may influence the progress of the process.
A DLBC lymphoma demonstrating both BCL-6 and c-MYC
rearrangements was clinically aggressive, resulting in the patient's
death 7 months after diagnosis. This might suggest that this combi-
nation of genetic events precipitates a tumour of poor prognostic
implications.
In conclusion, our work has illustrated that associations exist
between specific genomic alterations and defined subtypes of
NHL. In addition, we report the interesting finding of coexisting
rearrangements in a large percentage of the BCL-6-rearrangement-
positive lymphoma cases. The identification of these molecular
markers can be exploited in the diagnostic field, as well as aiding
our understanding of the molecular pathogenesis of the diverse
histological subtypes of NHL. Such markers may, in the future, be
used to stratify lymphoma patients into different subgroups that
share common genetic profiles. This novel classification scheme
may then allow more accurate prediction of tumour biologies.
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